Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

Fig. 1

Description of participants, study regimens, and study products included in the cross-protocol analysis of three studies. Blue boxes represent single VRC07-523LS administration regimens, orange boxes represent regimens with VRC07-523LS administered in combination with one or two other mAbs. The combination group received the mAbs sequentially, with VRC07-523LS being given last in all cases. *Indicates administration of the mAbs once at month 0. **Indicates administration of the mAbs twice: at month 0 and at month 4. Abbreviations: IV- intravenous; SC- subcutaneous, SPA-study product administration

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us